At today's #ASCOGU poster session: @danafarbernews.bsky.social’s Xiao Wei, MD, presents on the effectiveness of systemic therapies after Lu-PSMA-617 treatment in patients with metastatic castration-resistant prostate cancer.
February 26, 2026 at 5:00 PM
At today's #ASCOGU poster session: @danafarbernews.bsky.social’s Xiao Wei, MD, presents on the effectiveness of systemic therapies after Lu-PSMA-617 treatment in patients with metastatic castration-resistant prostate cancer.
Oooh these look intriguing. I had to read the last one twice because Enzalutamide?! Is this SABCS or ASCOGU 😁
December 5, 2024 at 5:45 AM
Oooh these look intriguing. I had to read the last one twice because Enzalutamide?! Is this SABCS or ASCOGU 😁
Research at #ASCOGU: @danafarber.bsky.social’s Dr. Alicia Morgans provides insights from the ARANOTE trial during a poster session. The poster looks at the impact of hospitalizations on health-related quality of life and overall survival in metastatic castration-sensitive prostate cancer.
February 27, 2026 at 7:30 PM
Research at #ASCOGU: @danafarber.bsky.social’s Dr. Alicia Morgans provides insights from the ARANOTE trial during a poster session. The poster looks at the impact of hospitalizations on health-related quality of life and overall survival in metastatic castration-sensitive prostate cancer.
🔥 #TestisCancer highlight from #ASCOGU!
📌 Abstract 618 – Final results of the #COTRIMS trial: Retroperitoneal lymphadenectomy in metastatic #Seminoma.
Important data for #GermCellTumors! What’s your take?
📌 Abstract 618 – Final results of the #COTRIMS trial: Retroperitoneal lymphadenectomy in metastatic #Seminoma.
Important data for #GermCellTumors! What’s your take?
February 8, 2025 at 9:30 AM
🔥 #TestisCancer highlight from #ASCOGU!
📌 Abstract 618 – Final results of the #COTRIMS trial: Retroperitoneal lymphadenectomy in metastatic #Seminoma.
Important data for #GermCellTumors! What’s your take?
📌 Abstract 618 – Final results of the #COTRIMS trial: Retroperitoneal lymphadenectomy in metastatic #Seminoma.
Important data for #GermCellTumors! What’s your take?
Pfizer's prostate cancer clinical trial results have leaked before their presentation at ASCO on Thursday, showing their drug cut the risk of disease progression by around half when added on top of a hormone therapy.
endpts.com/ascogu-pfize...
endpts.com/ascogu-pfize...
Pfizer’s prostate cancer data leak shows promising results in early-stage study
Leaked Pfizer Phase 1 trial shows mevrometostat plus Xtandi reduced prostate cancer progression risk by 49%. Data sparked interest in Oric Pharmaceuticals' similar drug candidate.
endpts.com
February 11, 2025 at 3:19 PM
Pfizer's prostate cancer clinical trial results have leaked before their presentation at ASCO on Thursday, showing their drug cut the risk of disease progression by around half when added on top of a hormone therapy.
endpts.com/ascogu-pfize...
endpts.com/ascogu-pfize...
🚀 Key #UrothelialCancer abstracts from #ASCOGU!
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.
February 8, 2025 at 9:29 AM
🚀 Key #UrothelialCancer abstracts from #ASCOGU!
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.
Dual antiangiogenic therapy for previously treated kidney cancer significantly improved progression-free survival versus a single drug, a large randomized trial showed.
http://medpagetoday.com/meetingcoverage/ascogu/120094
http://medpagetoday.com/meetingcoverage/ascogu/120094
Improved PFS in Advanced Kidney Cancer With Antiangiogenic Combination
Belzutifan-lenvatinib slows progression versus cabozantinib with much longer response duration
medpagetoday.com
March 4, 2026 at 12:23 AM
Dual antiangiogenic therapy for previously treated kidney cancer significantly improved progression-free survival versus a single drug, a large randomized trial showed.
http://medpagetoday.com/meetingcoverage/ascogu/120094
http://medpagetoday.com/meetingcoverage/ascogu/120094
🔥 Exciting #ProstateCancer Abstracts from #ASCOGU:
📌 LBA18 – Final overall survival results of the phase 3 #TALAPRO2 trial.
📌 Abstract 21 – Transdermal #Estradiol (#tE2) patches + #ARPIs in metastatic (#M1) prostate cancer.
📌 Abstract 22 – #Metastases-directed therapy in oligometastatic #CRPC.
📌 LBA18 – Final overall survival results of the phase 3 #TALAPRO2 trial.
📌 Abstract 21 – Transdermal #Estradiol (#tE2) patches + #ARPIs in metastatic (#M1) prostate cancer.
📌 Abstract 22 – #Metastases-directed therapy in oligometastatic #CRPC.
February 8, 2025 at 9:28 AM
🔥 Exciting #ProstateCancer Abstracts from #ASCOGU:
📌 LBA18 – Final overall survival results of the phase 3 #TALAPRO2 trial.
📌 Abstract 21 – Transdermal #Estradiol (#tE2) patches + #ARPIs in metastatic (#M1) prostate cancer.
📌 Abstract 22 – #Metastases-directed therapy in oligometastatic #CRPC.
📌 LBA18 – Final overall survival results of the phase 3 #TALAPRO2 trial.
📌 Abstract 21 – Transdermal #Estradiol (#tE2) patches + #ARPIs in metastatic (#M1) prostate cancer.
📌 Abstract 22 – #Metastases-directed therapy in oligometastatic #CRPC.
"LITESPARK-022 is the first adjuvant trial in kidney cancer to show a benefit for a combination versus a PD-1 agent alone." @danafarber.bsky.social’s Toni Choueiri, MD, featured in Fierce Pharma discussing kidney cancer research he presented at #ASCOGU.
➡️ bit.ly/3MTz0nq
➡️ bit.ly/3MTz0nq
A new standard? Merck's Welireg combos deliver 1-2 punch to kidney cancer
The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs from Merck’s Litespark clinical trial program for Welireg. | The treatment landscape for clear cell renal cell carcinoma could be due for a shake-up following dual breakthroughs from Merck’s Litespark clinical trial program for Welireg. But one critical factor could hinder these Welireg regimens from shifting from potential treatment options to the universal standard of care.
bit.ly
March 3, 2026 at 3:30 PM
"LITESPARK-022 is the first adjuvant trial in kidney cancer to show a benefit for a combination versus a PD-1 agent alone." @danafarber.bsky.social’s Toni Choueiri, MD, featured in Fierce Pharma discussing kidney cancer research he presented at #ASCOGU.
➡️ bit.ly/3MTz0nq
➡️ bit.ly/3MTz0nq
Expert analysis: Dr. Michael Serzan and Dr. Emre Yekedüz, both of @danafarbernews.bsky.social, preview the practice-changing data they expect this week at #ASCOGU.
Read more in @curetoday.bsky.social: bit.ly/46thzk5
Read more in @curetoday.bsky.social: bit.ly/46thzk5
Experts Preview Practice-Changing Data Ahead of 2026 ASCO GU | CURE
Oncologists highlight key 2026 ASCO GU studies in bladder, prostate, kidney and testicular cancers that could reshape treatment and personalize care.
bit.ly
February 25, 2026 at 4:30 PM
Expert analysis: Dr. Michael Serzan and Dr. Emre Yekedüz, both of @danafarbernews.bsky.social, preview the practice-changing data they expect this week at #ASCOGU.
Read more in @curetoday.bsky.social: bit.ly/46thzk5
Read more in @curetoday.bsky.social: bit.ly/46thzk5
Our Winter 2026 Genitourinary Oncology events are well underway, and the momentum continues. 👏
🎉 More sessions are happening tonight and tomorrow.
If you’re joining us, we look forward to continuing the conversation: https://bit.ly/49W3spJ
#ASCOGU #GenitourinaryOncology #CME #MedicalEducation
🎉 More sessions are happening tonight and tomorrow.
If you’re joining us, we look forward to continuing the conversation: https://bit.ly/49W3spJ
#ASCOGU #GenitourinaryOncology #CME #MedicalEducation
February 26, 2026 at 8:50 PM
Our Winter 2026 Genitourinary Oncology events are well underway, and the momentum continues. 👏
🎉 More sessions are happening tonight and tomorrow.
If you’re joining us, we look forward to continuing the conversation: https://bit.ly/49W3spJ
#ASCOGU #GenitourinaryOncology #CME #MedicalEducation
🎉 More sessions are happening tonight and tomorrow.
If you’re joining us, we look forward to continuing the conversation: https://bit.ly/49W3spJ
#ASCOGU #GenitourinaryOncology #CME #MedicalEducation
Read the latest insights from #GU26
From genomic predictors to real‑world combination strategies, experts highlight TP53 status as a potential marker of benefit, broad activity across disease features, and evolving mCRPC approaches
ow.ly/tuHe50Ypb0U
#ASCOGU #ASCOGU2026 #MedEd #MedSky
From genomic predictors to real‑world combination strategies, experts highlight TP53 status as a potential marker of benefit, broad activity across disease features, and evolving mCRPC approaches
ow.ly/tuHe50Ypb0U
#ASCOGU #ASCOGU2026 #MedEd #MedSky
March 4, 2026 at 4:19 PM
Read the latest insights from #GU26
From genomic predictors to real‑world combination strategies, experts highlight TP53 status as a potential marker of benefit, broad activity across disease features, and evolving mCRPC approaches
ow.ly/tuHe50Ypb0U
#ASCOGU #ASCOGU2026 #MedEd #MedSky
From genomic predictors to real‑world combination strategies, experts highlight TP53 status as a potential marker of benefit, broad activity across disease features, and evolving mCRPC approaches
ow.ly/tuHe50Ypb0U
#ASCOGU #ASCOGU2026 #MedEd #MedSky
We're at #GU26! Stay informed on the latest research in #ProstateCancer and #BladderCancer with our live coverage from the event, plus keep an eye out for summary articles, free and on demand with Medthority 👀 #MedSky #ASCO #ASCOGU
ow.ly/HUNu50Ymiw3
ow.ly/HUNu50Ymiw3
February 26, 2026 at 9:14 AM
We're at #GU26! Stay informed on the latest research in #ProstateCancer and #BladderCancer with our live coverage from the event, plus keep an eye out for summary articles, free and on demand with Medthority 👀 #MedSky #ASCO #ASCOGU
ow.ly/HUNu50Ymiw3
ow.ly/HUNu50Ymiw3
ONCrg - What to Watch at ASCO GU
🚨 LIVE EVENT!
Register here: events.teams.microsoft.com/event/6cf5ce...
#ASCOGU #GU26 #ProstateCancer #BladderCancer #RCC
🚨 LIVE EVENT!
Register here: events.teams.microsoft.com/event/6cf5ce...
#ASCOGU #GU26 #ProstateCancer #BladderCancer #RCC
February 18, 2026 at 11:38 PM
ONCrg - What to Watch at ASCO GU
🚨 LIVE EVENT!
Register here: events.teams.microsoft.com/event/6cf5ce...
#ASCOGU #GU26 #ProstateCancer #BladderCancer #RCC
🚨 LIVE EVENT!
Register here: events.teams.microsoft.com/event/6cf5ce...
#ASCOGU #GU26 #ProstateCancer #BladderCancer #RCC
ONCrg is gearing up for ASCO GU 2026! If you’ll be attending and want to discuss how our reports can help you stay ahead of the curve in GU oncology, let’s connect. ONCrg Conference coverage: onc-rg.com/conferences/
#ASCOGU #GU26 #ProstateCancer #BladderCancer #RCC #OncologyCI #ONCrg #Genitourinary
#ASCOGU #GU26 #ProstateCancer #BladderCancer #RCC #OncologyCI #ONCrg #Genitourinary
February 18, 2026 at 11:32 PM
ONCrg is gearing up for ASCO GU 2026! If you’ll be attending and want to discuss how our reports can help you stay ahead of the curve in GU oncology, let’s connect. ONCrg Conference coverage: onc-rg.com/conferences/
#ASCOGU #GU26 #ProstateCancer #BladderCancer #RCC #OncologyCI #ONCrg #Genitourinary
#ASCOGU #GU26 #ProstateCancer #BladderCancer #RCC #OncologyCI #ONCrg #Genitourinary
We just launched our second GU cancer module. #BladderCancer is now live on Oncoscope-AI, joining our existing #ProstateCancer module.
If you treat GU cancers or work with teams preparing for #ASCOGU, request FREE access at the link in bio.
Read more here: bit.ly/4qb8gfP
If you treat GU cancers or work with teams preparing for #ASCOGU, request FREE access at the link in bio.
Read more here: bit.ly/4qb8gfP
February 3, 2026 at 3:09 PM
We just launched our second GU cancer module. #BladderCancer is now live on Oncoscope-AI, joining our existing #ProstateCancer module.
If you treat GU cancers or work with teams preparing for #ASCOGU, request FREE access at the link in bio.
Read more here: bit.ly/4qb8gfP
If you treat GU cancers or work with teams preparing for #ASCOGU, request FREE access at the link in bio.
Read more here: bit.ly/4qb8gfP
Excellentes 1res Journées d’Actualités Normandes en Onco-Urologie – #JANOU2025 !
Toutes les nouveautés prostate, rein, vessie + grands changements 2025 (#CCAFU #ASCOGU).
Médecins, urologues, oncologues, radiothérapeutes réunis !
#OncoUrologie #Urologie #Oncologie #Normandie
Toutes les nouveautés prostate, rein, vessie + grands changements 2025 (#CCAFU #ASCOGU).
Médecins, urologues, oncologues, radiothérapeutes réunis !
#OncoUrologie #Urologie #Oncologie #Normandie
April 26, 2025 at 8:41 AM
Excellentes 1res Journées d’Actualités Normandes en Onco-Urologie – #JANOU2025 !
Toutes les nouveautés prostate, rein, vessie + grands changements 2025 (#CCAFU #ASCOGU).
Médecins, urologues, oncologues, radiothérapeutes réunis !
#OncoUrologie #Urologie #Oncologie #Normandie
Toutes les nouveautés prostate, rein, vessie + grands changements 2025 (#CCAFU #ASCOGU).
Médecins, urologues, oncologues, radiothérapeutes réunis !
#OncoUrologie #Urologie #Oncologie #Normandie
Welche Highlights wurden auf dem #ASCO 2025 vorgestellt, medtoday fasst für Sie alle Highlights zusammen!
medtoday.de
#ASCOGU #Medizin #Forschung
medtoday.de
#ASCOGU #Medizin #Forschung
February 20, 2025 at 2:55 PM
Welche Highlights wurden auf dem #ASCO 2025 vorgestellt, medtoday fasst für Sie alle Highlights zusammen!
medtoday.de
#ASCOGU #Medizin #Forschung
medtoday.de
#ASCOGU #Medizin #Forschung
What does it take to bring AI into real clinical care?
Great discussion from #ASCOGU on how tools like the #ArteraAI Prostate Test are already shaping decisions today, with potential across cancers.
Watch the interview: buff.ly/q3CHHnb
#ProstateCancer #PrecisionMedicine
Great discussion from #ASCOGU on how tools like the #ArteraAI Prostate Test are already shaping decisions today, with potential across cancers.
Watch the interview: buff.ly/q3CHHnb
#ProstateCancer #PrecisionMedicine
June 3, 2026 at 7:05 PM
What does it take to bring AI into real clinical care?
Great discussion from #ASCOGU on how tools like the #ArteraAI Prostate Test are already shaping decisions today, with potential across cancers.
Watch the interview: buff.ly/q3CHHnb
#ProstateCancer #PrecisionMedicine
Great discussion from #ASCOGU on how tools like the #ArteraAI Prostate Test are already shaping decisions today, with potential across cancers.
Watch the interview: buff.ly/q3CHHnb
#ProstateCancer #PrecisionMedicine
Thoughts on this? >> #ASCOGU: Lilly’s early bladder cancer data hint at safety
edge over J&J’s Balversa: Eli Lilly has shared first-in-human results for its selective FGFR3… >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare
edge over J&J’s Balversa: Eli Lilly has shared first-in-human results for its selective FGFR3… >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare
#ASCOGU: Lilly’s early bladder cancer data hint at safety
edge over J&J’s Balversa
Eli Lilly has shared first-in-human results for its selective FGFR3 inhibitor in a subset of bladder cancer patients, marking the start of a program that could eventually challenge Johnson & Johnson’s Balversa. Balversa is marketed ...
dlvr.it
February 15, 2025 at 12:41 AM
Thoughts on this? >> #ASCOGU: Lilly’s early bladder cancer data hint at safety
edge over J&J’s Balversa: Eli Lilly has shared first-in-human results for its selective FGFR3… >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare
edge over J&J’s Balversa: Eli Lilly has shared first-in-human results for its selective FGFR3… >> Comment below! #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare